News
Temperature Mapping for GMP Warehouses: What Auditors Expect to See
Temperature mapping is one of the most frequently inspected elements of GMP warehouse qualification, and the gap between documentation that satisfies an auditor and documentation that raises questions is often a matter of how well the mapping study was...
Business & Industry
ACHEMA 2027 Strengthens India Process Industry Collaboration
DECHEMA, EEPC INDIA and Messe Frankfurt India brought together more than 200 industry leaders, business stakeholders and professionals from India’s process, chemical, pharmaceutical and engineering sectors at a Networking Evening in New Delhi on 8 September 2026. Held at...
News
Onyx Scientific Boosts API Manufacturing Capacity in UK
Onyx Scientific, a global small molecule CDMO, is investing more than £1.5m to expand its Good Manufacturing Practice (GMP) facilities and increase commercial active pharmaceutical ingredient (API) production at its Sunderland UK facility. The expansion will add four GMP...
Business & Industry
Strengthening Supply Chain Visibility for Safe Medicines
A comprehensive survey of 5,000 patients across the United States, the United Kingdom, France, and Germany indicates that pharmaceutical manufacturers have a timely opportunity to build consumer trust through enhanced traceability. With six in 10 respondents voicing concern that...
Business & Industry
Novo Nordisk and Orbis Medicines Partner on Oral Therapies for Cardiometabolic Diseases
Danish pharmaceutical company Novo Nordisk and biotechnology developer Orbis Medicines have entered into a drug discovery and licensing agreement valued at up to $1.4 billion to develop oral therapies for cardiometabolic diseases. The program aims to advance oral alternatives...
News
Top 5 AI Molecule Design Software Platforms in 2026
Generating a molecule is easy for a modern AI model. Generating one that a discovery team should actually make is considerably harder. A useful candidate has to satisfy several constraints at once. It may need stronger binding without losing...
Business & Industry
FDA Opens Door to Innovative Approaches for Psychedelic Drug Development Amid Mental Health Crisis
Senior officials at the US Food and Drug Administration have signaled that the agency is open to novel and innovative approaches in the clinical development of psychedelic drugs, citing the worsening mental health crisis across the United States. The...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read